| 摘要 |
The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting. |
| 主权项 |
1. A method for treating hematological cancer in a patient with a cancer therapy regimen comprising:
a) measuring the level of expression of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive marker or markers numbered 1-547 in Table 1A, 658-871 in Table 1B, 873-876 in Table 1B, 912-1062 in Table 2A, 1071-1079, 1081-1087, 1089-1093, 1095-1106, 1108-1185 in Table 2B, and/or 1203-1423 in Table 3 in a patient sample comprising hematological tumor cells, wherein the sequences recognized by probesets of the predictive markers:
i) numbered 1-547 consist of SEQ ID NOs: 1-513,ii) numbered 658-871 and 873-876 consist of SEQ ID NOs:614-830,iii) numbered 912-1062 consist of SEQ ID NOs:866-1014, 434 and 733,iv) numbered 1071-1079, 1081-1087, 1089-1093, 1095-1106 and 1108-1185 consist of SEQ ID NOs:1023-1133, andv) numbered 1203-1423 consist of SEQ ID NOs:201, 398, 1091 and 1151-1365; b) comparing the level of expression of the at least one nucleic acid sequence to a reference expression level of that sequence to determine whether the level of expression of the at least one nucleic acid sequence is upregulated in the patient sample comprising tumor cells, thereby identifying whether expression in the sample includes a profile of expression of the predictive marker or markers; and c) treating the patient with the cancer therapy regimen if the expression profile indicates responsiveness to the cancer therapy regimen,wherein the cancer therapy regimen is proteasome inhibition-based therapy and/or glucocorticoid based therapy. |
